Compounds as peptidic GLP1/glucagon/GIP receptor agonists

US10519211B2 · kind B2 · utility

Assignee

• Sanofi · FR

Inventors

• Martin Bossart · Frankfurt am Main, DE
• Andreas Evers · Frankfurt am Main, DE
• Torsten Haack · Frankfurt am Main, DE
• Katrin Lorenz · Frankfurt am Main, DE
• Dieter Kadereit · Kelkheim, DE
• Michael Wagner · Frankfurt am Main, DE
• Stefania PFEIFFER-MAREK · Frankfurt, DE
• Martin Lorenz · Frankfurt am Main, DE

Key dates

• Filing date: Dec 1, 2017
• Grant date: Dec 31, 2019
• Expiry date: Dec 1, 2037

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K14/605
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention relates to trigonal GLP-1/glucagon/GIP receptor agonists and their medical use, for example in the treatment of disorders of the metabolic syndrome, including diabetes and obesity, as well as for reduction of excess food intake.